Related Experiment Videos
Clot-selective coronary thrombolysis with tissue-type plasminogen activator
Science (New York, N.Y.)
|June 10, 1983
Summary
Rapid coronary thrombolysis using tissue-type plasminogen activator effectively dissolved clots and restored blood flow in dogs. This intervention prevented heart attack damage without causing systemic bleeding risks.
Area of Science:
- Cardiovascular Research
- Biomedical Science
- Pharmacology
Background:
- Acute myocardial infarction (heart attack) causes significant damage due to blocked coronary arteries.
- Timely restoration of blood flow is crucial to minimize myocardial injury.
- Existing thrombolytic therapies have limitations, necessitating improved agents.
Purpose of the Study:
- To evaluate the efficacy of clot-selective tissue-type plasminogen activator in achieving rapid coronary thrombolysis.
- To assess the impact of this agent on myocardial metabolism and blood flow.
- To determine if the agent induces a systemic fibrinolytic state.
Main Methods:
- Intravenous administration of tissue-type plasminogen activator in a canine model of acute myocardial infarction.
- Coronary thrombolysis assessment within 10 minutes.
- Noninvasive detection of myocardial blood flow and intermediary metabolism using positron tomography.
- Monitoring for systemic fibrinolytic state.
Main Results:
- Successful coronary thrombolysis was achieved within 10 minutes.
- Tissue-type plasminogen activator restored intermediary metabolism and nutritional myocardial blood flow.
- The agent did not induce a systemic fibrinolytic state, indicating clot selectivity.
- Positron tomography confirmed improved myocardial perfusion noninvasively.
Conclusions:
- Clot-selective tissue-type plasminogen activator is a highly effective agent for rapid coronary thrombolysis.
- This agent can quickly restore myocardial perfusion and metabolism after infarction.
- Its clot selectivity offers a potential safety advantage by avoiding systemic fibrinolysis.